Mineralys Therapeutics announced on March 11, 2025, the pricing of an underwritten public offering of 12,962,962 shares of its common stock at a public offering price of $13.50 per share. The aggregate gross proceeds from the offering are expected to be approximately $175.0 million.
The company also granted the underwriters a 30-day option to purchase up to an additional 1,944,444 shares of common stock. The offering was expected to close on or about March 13, 2025, subject to customary closing conditions.
The net proceeds from this offering are intended to fund the clinical development of lorundrostat, including research and development and manufacturing, as well as pre-commercialization activities, working capital, and general corporate purposes. This capital infusion is crucial for advancing the company's pipeline.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.